News
ENVB
0.8950
-0.56%
-0.0050
Weekly Report: what happened at ENVB last week (0415-0419)?
Weekly Report · 5d ago
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
DEA Revisits Proposed Ban On Two Psychedelic Compounds: Researchers Disagree, Insist on Hearings. The Drug Enforcement Administration is revisiting its stance on the classification of two psychedelic compounds. The agency has proposed both be listed as Schedule I substances with no recognized medical use. Benzinga Psychedelics Podcast features an expert on the ancient healing plant kanna.
Benzinga · 04/17 12:42
New Strong Buy Stocks for April 17th
NASDAQ · 04/17 11:26
Weekly Report: what happened at ENVB last week (0408-0412)?
Weekly Report · 04/15 09:33
New Strong Buy Stocks for April 12th
NASDAQ · 04/12 11:29
Weekly Report: what happened at ENVB last week (0401-0405)?
Weekly Report · 04/08 09:35
Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Ulta Beauty shares dipped 13.7% to $448.08 on Wednesday. The company reportedly issued a weak outlook at the J.P. Morgan Retail Roundup investor conference. ARCA biopharma, Inc. Shares climbed 108% in the mid-day session.
Benzinga · 04/03 17:56
FibroGen, Acorda Therapeutics, Enveric Biosciences among healthcare movers
Healthcare On the Move: FibroGen, Acorda Therapeutics, Enveric Biosciences among healthcare movers. S&P 500 Health Care Sector +0.26% to 1685.56. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index.
Seeking Alpha · 04/03 14:00
SOL, MESO and ACOR among pre-market losers
SOL, MESO and ACOR among pre-market losers. View reaches deal with Cantor Fitzgerald and RXR to become a private company. BCAN, HWH, ANGH, PTPI, MDAI, VIEW, and VIEW are also losers.
Seeking Alpha · 04/03 12:12
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
ARCA biopharma (NASDAQ:ABIO) stock moved upwards by 124.6% to $3.84 during Wednesday's pre-market session. Kintara Therapeutics and Aesthetic Medical Intl were the biggest gainers. SINTX Techs stock declined by 21.0% during the day.
Benzinga · 04/03 12:09
12 Health Care Stocks Moving In Tuesday's After-Market Session
OneMedNet (NASDAQ:ONMD) shares moved upwards by 75.9% to $1.39 during Tuesday's after-market session. Aesthetic Medical Intl shares rose 43.48% and Sight Sciences shares rose 20.77%. Losers Enveric Biosciences, Acorda Therapeutics and Cutera were among the losers.
Benzinga · 04/02 20:31
ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q4 2023
Enveric Biosciences reported results for the fourth quarter of 2023. The company did not report any revenue for the quarter. Enveric reported earnings per share of -$1.47, above the analyst estimate for EPS of - $1.54.
Investorplace · 04/01 14:53
Weekly Report: what happened at ENVB last week (0325-0329)?
Weekly Report · 04/01 09:35
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Utah hospitals will soon provide psilocybin and MDMA therapy for mental health conditions in a pilot program. Beckley Psytech and atai announce positive initial results from a clinical trial of 5-MeO-DMT in Treatment Resistant Depression. Prosecutors in Virginia are probing whether Facebook's social media platforms are facilitating the illegal sale of drugs. Elon Musk makes the case for using psychedelics in a new episode of the Benzinga Psychedelics Podcast.
Benzinga · 03/29 16:43
Enveric Biosciences Inc <ENVB.OQ> expected to post a loss of $1.28 a share - Earnings Preview
Enveric Biosciences Inc expected to post a loss of $1.28 a share - Earnings Preview. The company is expected to report results on May 13 for the period ending March 31 2024. The mean analyst estimate for Enveric is for the company to lose $ 1.28 per share.
Reuters · 03/27 20:03
Enveric Biosciences Optimistic On Q4 And Full-Year Results: 'Psychedelic-Inspired' Meds For Future Growth
Enveric Biosciences shares financial results for the fourth quarter of 2023 and the fiscal year ended December 31, 2023. Nasdaq-listed psychedelics biotech Enveric is advancing two drug candidates for depression and anxiety disorders. The company has discovered over 1,000 psychedelic-inspired compounds in the past year.
Benzinga · 03/27 12:59
Enveric Biosciences reports Q4 results
Seeking Alpha · 03/26 12:43
Enveric Biosciences Inc: Current report
Press release · 03/26 12:35
*Enveric Biosciences 4Q Loss $3.44M >ENVB
Dow Jones · 03/26 11:02
Press Release: Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023
Enveric Biosciences reports financial results for the fourth quarter of 2023 and fiscal year ended December 31, 2023. Selected neuroplastogen lead candidate EB-003 as a potential first-in-class therapeutic option for depression and anxiety disorders. Company continues to progress IND-enabling preclinical work for EB-002.
Dow Jones · 03/26 11:01
More
Webull provides a variety of real-time ENVB stock news. You can receive the latest news about Enveric Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About ENVB
Enveric Biosciences, Inc. is a biotechnology company. The Company is engaged in the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety and addiction disorders. The Company, through Psybrary has created a robust intellectual property (IP) portfolio of new chemical entities for specific mental health indications. Its lead program, the EVM201 Series, comprises synthetic prodrugs of the active metabolite, psilocin. It is developing the first product from the EVM201 Series, EB-002, for the treatment of psychiatric disorders. The Company is also advancing its second program, the EVM301 Series, EB 003, which is an approach to the treatment of difficult-to-address mental health disorders. Within the Psybrary, it has three different types of molecules, Generation 1 (classic psychedelics), Generation 2 (pro-drugs), and Generation 3 (new chemical entities). It has created over 1,000 novel psychedelic molecular compounds and derivatives.